(SKIN) Beauty Health - Ratings and Ratios
HydraFacial, Syndeo Devices, Consumables, SkinStylus, Keravive
SKIN EPS (Earnings per Share)
SKIN Revenue
Description: SKIN Beauty Health
The Beauty Health Company (SKIN) is a global player in the esthetic technology and products market, operating across multiple regions including the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Its flagship product, HydraFacial, is a proprietary skin treatment technology that cleanses, extracts, and hydrates the skin. The company has a diversified product portfolio, including Syndeo devices, consumables, SkinStylus SteriLock Microsystem, and Keravive peptide solutions, catering to various skin concerns and needs.
From a business perspective, the companys focus on innovation and personalization is evident through its product offerings and the MyBeautyHealth mobile application. The app enables consumers to earn loyalty points, log skin concerns, receive personalized treatment plans, and connect with Hydrafacial providers. This direct-to-consumer engagement strategy likely enhances customer retention and acquisition. Key Performance Indicators (KPIs) to monitor could include customer retention rates, average revenue per user (ARPU), and the number of active users on the MyBeautyHealth app.
To evaluate the companys financial health and growth prospects, we can examine metrics such as revenue growth rate, gross margin, operating expenses as a percentage of revenue, and return on equity (ROE). Given the companys current ROE of -67.93%, it is likely that the company is investing heavily in growth initiatives, which may negatively impact short-term profitability. The forward P/E ratio of 25.51 suggests that investors expect future growth, potentially driven by the companys expanding product portfolio and increasing global presence.
From a competitive landscape perspective, the personal care products industry is highly competitive, with numerous players competing for market share. The Beauty Health Companys focus on esthetic technologies and personalized solutions may provide a differentiation advantage. Monitoring market share, competitor activity, and consumer trends will be essential to understanding the companys relative performance and identifying opportunities for growth.
SKIN Stock Overview
| Market Cap in USD | 274m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 2020-11-24 |
SKIN Stock Ratings
| Growth Rating | -34.0% |
| Fundamental | 47.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.29% |
| Analyst Rating | 2.78 of 5 |
SKIN Dividends
Currently no dividends paidSKIN Growth Ratios
| Growth Correlation 3m | 49% |
| Growth Correlation 12m | 26.5% |
| Growth Correlation 5y | -86.1% |
| CAGR 5y | -29.40% |
| CAGR/Max DD 5y | -0.30 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | -5.33 |
| Beta | 1.459 |
| Volatility | 79.76% |
| Current Volume | 516.7k |
| Average Volume 20d | 629.9k |
| Stop Loss | 1.9 (-8.7%) |
| Signal | 1.40 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-19.0m TTM) > 0 and > 6% of Revenue (6% = 18.6m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 5.96pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 79.55% (prev 113.1%; Δ -33.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 39.4m > Net Income -19.0m (YES >=105%, WARN >=100%) |
| Net Debt (164.7m) to EBITDA (20.7m) ratio: 7.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (140.3m) change vs 12m ago -1.15% (target <= -2.0% for YES) |
| Gross Margin 61.50% (prev 33.42%; Δ 28.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.86% (prev 51.44%; Δ -0.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.60 (EBITDA TTM 20.7m / Interest Expense TTM 11.6m) >= 6 (WARN >= 3) |
Altman Z'' -1.30
| (A) 0.49 = (Total Current Assets 306.1m - Total Current Liabilities 59.4m) / Total Assets 507.6m |
| (B) -0.98 = Retained Earnings (Balance) -498.3m / Total Assets 507.6m |
| (C) -0.01 = EBIT TTM -6.97m / Avg Total Assets 609.7m |
| (D) -1.15 = Book Value of Equity -500.5m / Total Liabilities 433.6m |
| Total Rating: -1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 47.01
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 8.48% = 4.24 |
| 3. FCF Margin 11.76% = 2.94 |
| 4. Debt/Equity 4.98 = -2.50 |
| 5. Debt/Ebitda 17.78 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -32.83% = -2.50 |
| 8. Rev. Trend -65.47% = -3.27 |
| 9. Rev. CAGR -4.52% = -0.75 |
| 10. EPS Trend 14.16% = 0.35 |
| 11. EPS CAGR 660.3% = 2.50 |
What is the price of SKIN shares?
Over the past week, the price has changed by -5.88%, over one month by +23.08%, over three months by +29.19% and over the past year by +14.29%.
Is Beauty Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SKIN is around 1.62 USD . This means that SKIN is currently overvalued and has a potential downside of -22.12%.
Is SKIN a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 7
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the SKIN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1.9 | -9.6% |
| Analysts Target Price | 1.8 | -15.4% |
| ValueRay Target Price | 1.9 | -10.6% |
Last update: 2025-08-21 02:50
SKIN Fundamental Data Overview
CCE Cash And Equivalents = 212.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 107.5269
P/S = 0.8835
P/B = 3.7018
P/EG = 0.9535
Beta = 1.204
Revenue TTM = 310.1m USD
EBIT TTM = -6.97m USD
EBITDA TTM = 20.7m USD
Long Term Debt = 363.1m USD (from longTermDebt, last quarter)
Short Term Debt = 5.17m USD (from shortTermDebt, last quarter)
Debt = 368.3m USD (Calculated: Short Term 5.17m + Long Term 363.1m)
Net Debt = 164.7m USD (from netDebt column, last quarter)
Enterprise Value = 430.2m USD (273.9m + Debt 368.3m - CCE 212.0m)
Interest Coverage Ratio = -0.60 (Ebit TTM -6.97m / Interest Expense TTM 11.6m)
FCF Yield = 8.48% (FCF TTM 36.5m / Enterprise Value 430.2m)
FCF Margin = 11.76% (FCF TTM 36.5m / Revenue TTM 310.1m)
Net Margin = -6.13% (Net Income TTM -19.0m / Revenue TTM 310.1m)
Gross Margin = 61.50% ((Revenue TTM 310.1m - Cost of Revenue TTM 119.4m) / Revenue TTM)
Tobins Q-Ratio = -0.86 (set to none) (Enterprise Value 430.2m / Book Value Of Equity -500.5m)
Interest Expense / Debt = 1.13% (Interest Expense 4.14m / Debt 368.3m)
Taxrate = -5.30% (set to none) (from quarterly Income Tax Expense: -993.0k / 18.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 5.15 (Total Current Assets 306.1m / Total Current Liabilities 59.4m)
Debt / Equity = 4.98 (Debt 368.3m / last Quarter total Stockholder Equity 74.0m)
Debt / EBITDA = 17.78 (Net Debt 164.7m / EBITDA 20.7m)
Debt / FCF = 10.10 (Debt 368.3m / FCF TTM 36.5m)
Total Stockholder Equity = 57.9m (last 4 quarters mean)
RoA = -3.74% (Net Income -19.0m, Total Assets 507.6m )
RoE = -32.83% (Net Income TTM -19.0m / Total Stockholder Equity 57.9m)
RoCE = -1.66% (Ebit -6.97m / (Equity 57.9m + L.T.Debt 363.1m))
RoIC = unknown (NOPAT none, Invested Capital 562.8m, Ebit -6.97m)
WACC = unknown (E(273.9m)/V(642.2m) * Re(11.39%)) + (D(368.3m)/V(642.2m) * Rd(1.13%) * (1-Tc(none)))
Shares Correlation 5-Years: -40.0 | Cagr: -1.04%
Discount Rate = 11.39% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 57.02% ; FCFE base≈25.4m ; Y1≈16.7m ; Y5≈7.62m
Fair Price DCF = 0.75 (DCF Value 95.6m / Shares Outstanding 126.8m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -65.47 | Revenue CAGR: -4.52%
Rev Growth-of-Growth: -12.44
EPS Correlation: 14.16 | EPS CAGR: 660.3%
EPS Growth-of-Growth: 122.4
Additional Sources for SKIN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle